• 1
    Fusshoeller A. Histomorphological and functional changes of the peritoneal membrane during long-term peritoneal dialysis. Pediatr Nephrol 2008;23:1925.
  • 2
    Goffin E. Peritoneal membrane structural and functional changes during peritoneal dialysis. Semin Dial 2008;21:25865.
  • 3
    Summers AM, Hoff CM, Topley N. How can genetic advances impact on experimental models of encapsulating peritoneal sclerosis? Perit Dial Int 2008;5:S1620.
  • 4
    Schmidt DW, Flessner MF. Pathogenesis and treatment of encapsulating peritoneal sclerosis: basic and translational research. Perit Dial Int 2008;28(Suppl. 5):S105.
  • 5
    Augustine T, Brown PW, Davies SD, Summers AM, Wilkie ME. Encapsulating peritoneal sclerosis: clinical significance and implications. Nephron Clin Pract 2009;111:c14954.
  • 6
    Park SH, Kim YL, Lindholm B. Experimental encapsulating peritoneal sclerosis models: pathogenesis and treatment. Perit Dial Int 2008;28(Suppl. 5):S218.
  • 7
    Witowski J, Jörres A. Preventing peritoneal fibrosis – an ace up our sleeve? Perit Dial Int 2005;25:259.
  • 8
    Noh H, Ha H, Yu MR, Kim YO, Kim JH, Lee HB. Angiotensin II mediates high glucose-induced TGF-beta1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int 2005;25:3847.
  • 9
    Weber KT, Swamynathan SK, Guntaka RV, Sun Y. Angiotensin II and extracellular matrix homeostasis. Int J Biochem Cell Biol 1999;31:395403.
  • 10
    Kaneko K, Hamada C, Tomino Y. Peritoneal fibrosis intervention. Perit Dial Int 2007;27(Suppl. 2):S826.
  • 11
    Müller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006;1:2218.
  • 12
    Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008;7:399410.
  • 13
    Chen TM, Subeq YM, Lee RP, Chiou TW, Hsu BG. Single dose intravenous thioacetamide administration as a model of acute liver damage in rats. Int J Exp Pathol 2008;89:22331.
  • 14
    Lee CC, Lee RP, Subeq YM, Lee CJ, Chen TM, Hsu BG. Fluvastatin attenuates severe hemorrhagic shock-induced organ damage in rats. Resuscitation 2009;80:3728.
  • 15
    Subeq YM, Wu WT, Lee CJ, Lee RP, Yang FL, Hsu BG. Pentobarbital reduces rhabdomyolysis induced acute renal failure in conscious rats. J Trauma 2009;67:1328.
  • 16
    Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005;23:41726.
  • 17
    Ro Y, Hamada C, Inaba M, Io H, Kaneko K, Tomino Y. Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transplant 2007;22:283848.
  • 18
    Komatsu H, Uchiyama K, Tsuchida M, Isoyama N, Matsumura M, Hara T et al. Development of a peritoneal sclerosis rat model using a continuous-infusion pump. Perit Dial Int 2008;28:6417.
  • 19
    Saito H, Kitamoto M, Kato K, Liu N, Kitamura H, Uemura K et al. Tissue factor and factor v involvement in rat peritoneal fibrosis. Perit Dial Int 2009;29:34051.
  • 20
    Di Paolo N, Nicolai GA, Garosi G. The peritoneum: from histological studies to mesothelial transplant through animal experimentation. Perit Dial Int 2008;28(Suppl. 5):S59.
  • 21
    Suga H, Teraoka S, Ota K, Komemushi S, Furutani S, Yamauchi S et al. Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp Toxicol Pathol 1995;47:28791.
  • 22
    Nishino T, Miyazaki M, Abe K, Furusu A, Mishima Y, Harada T et al. Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats. Kidney Int 2003;64:88796.
  • 23
    Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 2004;65:192736.
  • 24
    Faull RJ. Bad and good growth factors in the peritoneal cavity. Nephrology 2005;10:2349.
  • 25
    Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TR, Gauldie J. Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol 2001;12:202939.
  • 26
    Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008;52:1306.
  • 27
    Bozkurt D, Cetin P, Sipahi S, Hur E, Nar H, Ertilav M et al. The effects of renin-angiotensin system inhibition on regression of encapsulating peritoneal sclerosis. Perit Dial Int 2008;28(Suppl. 5):S3842.
  • 28
    Wood JM, Maibaum J, Rahuel J, Grütter MG, Cohen NC, Rasetti V et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003;308:698705.
  • 29
    Kyuden Y, Ito T, Masaki T, Yorioka N, Kohno N. TGF-beta1 induced by high glucose is controlled by angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on cultured human peritoneal mesothelial cells. Perit Dial Int 2005;25:48391.
  • 30
    Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007;13(8 Suppl. B):920.
  • 31
    Berl T. Review: renal protection by inhibition of the renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst 2009;10:18.